Ipratropium Adultes Arrow (Ipratropium Bromide)

Ipratropium bromide blocks muscarinic (M1 and M3) receptors on airway smooth muscle, preventing acetylcholine‑induced contraction. This inhibition leads to bronchodilation, reduced airway resistance, and better airflow without stimulating beta‑adrenergic pathways.

The specific dose and frequency are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Dosing instructions are provided on the prescription label and should be followed exactly as directed by a healthcare professional.

Safety data for ipratropium bromide in pregnancy and lactation are limited. The prescriber should weigh potential benefits against possible risks and consider alternative therapies if appropriate. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ipratropium is an anticholinergic bronchodilator, whereas many alternatives such as albuterol are beta‑2 agonists. Ipratropium provides a longer‑acting, non‑beta‑stimulating option, which can be advantageous for patients who experience tachycardia with beta‑agonists or require combination therapy for additive bronchodilation.

Store the inhalation solution at room temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight, and extreme temperatures. Keep the container tightly closed when not in use to maintain product stability.

The medication is delivered via a metered‑dose inhaler or nebulizer, as directed by the prescribing clinician. Patients should inhale the dose slowly and deeply, following the device’s instructions, and rinse the mouth after use to reduce local irritation.

Serious adverse events, though rare, include paradoxical bronchospasm, angioedema, severe allergic reactions (anaphylaxis), and urinary retention. Patients should seek immediate medical attention if they experience sudden worsening of breathing, swelling of the face or throat, or difficulty urinating.

Ipratropium should be avoided in individuals with a known hypersensitivity to ipratropium bromide or other anticholinergic agents. Caution is also advised for patients with narrow‑angle glaucoma, severe urinary retention, or significant prostate enlargement, and it should be used only under medical supervision in these cases.